Active Surveillance for Cancer of the Prostate (ASCaP)
Launched by JONSSON COMPREHENSIVE CANCER CENTER · Jul 29, 2009
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The Active Surveillance for Cancer of the Prostate (ASCaP) trial is studying a careful monitoring approach for men with low-risk prostate cancer. This means that instead of starting treatment right away, doctors will regularly check the health of the cancer. If the cancer shows signs of growing or changing, then treatment can be started. This approach is different from "Watchful Waiting," which is more about comfort care for advanced cancer. The goal of this trial is to understand how effective Active Surveillance is in managing prostate cancer for men whose cancer is not currently causing problems.
To participate in this trial, men must be diagnosed with a specific type of prostate cancer and have localized tumors that haven't spread. They should not have received any previous treatments like surgery or radiation for their cancer and need to be willing to have regular check-ups and tests. Participants can expect to have regular visits with their healthcare team to monitor their health and the status of their cancer. It’s important for interested individuals to know that they should be in good health overall and have a life expectancy of at least two years to be eligible for the study.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Histologically confirmed adenocarcinoma of the prostate.
- • 2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
- • 3. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
- • 4. Patient has elected Active Surveillance as preferred management plan for prostate cancer.
- • 5. Patient consent has been obtained according to local Institutional Review Board .
- • 6. Patient is accessible and compliant for follow-up.
- Exclusion Criteria:
- • 1. Unwillingness or inability to undergo serial prostate biopsy.
- • 2. Overall life expectancy less than 2 years
- • 3. Advanced prostate cancer
About Jonsson Comprehensive Cancer Center
The Jonsson Comprehensive Cancer Center (JCCC) is a leading research and treatment institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials and cutting-edge research. Affiliated with the University of California, Los Angeles (UCLA), the JCCC integrates a multidisciplinary approach, bringing together experts in oncology, genetics, and public health to foster collaboration and translate scientific discoveries into effective therapies. With a commitment to improving patient outcomes and quality of life, the JCCC conducts a wide range of clinical trials aimed at addressing various cancer types, ensuring that patients have access to the most advanced therapeutic options available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Leonard S Marks, M.D.
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials